Primary Investigator: Richard Weachter, MD

Study Coordinator: Kathy Belew, CNS-BC

Status: Closed to entrollment - follow-up continues

Study Title: Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (AF)

Purpose: To determine if apixaban is noninferior to warfarin (INR target range 2.0 - 3.0) in the combined endpoint of stroke (ischemic or hemorrhagic or of unspecified type) and systemic embolism, in subjects with AF and at least one additional risk factor for stroke.

Actions: 
Call Kathy Belew (beeper 573-499-8063) and/or on-call research nurse (on-call beeper 573-499-8084) or Dr. Weachter if subject is admitted to the hospital or for any questions regarding study medication.